mTOR Signaling Combined with Cancer Stem Cell Markers as a Survival Predictor in Stage II Colorectal Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Wnt and mammalian target of rapamycin (mTOR) are major molecular signaling pathways associated with the development and progression of tumor, as well as the maintenance and proliferation of cancer stem cells (CSCs), in colorectal cancer (CRC). Identifying patients at risk of poor prognosis is important to determining whether to add adjuvant treatment in stage II CRC and thus improve survival. In the present study, we evaluated the prognostic value of Wnt, mTOR, and CSC markers as survival predictors in stage II CRC. Materials and Methods: We identified 148 cases of stage II CRC and acquired their tumor tissue. Tissue microarrays for immunohistochemical staining were constructed, and the expressions of CD166, CD44, EphB2, β-catenin, pS6 were evaluated using immunohistochemical staining. Results: The expressions of CD166 (p=0.045) and pS6 (p=0.045) and co-expression of pS6/CD166 (p=0.005), pS6/CD44 (p=0.042), and pS6/CD44/CD166 (p=0.013) were negatively correlated with cancer-specific survival. Cox proportional hazard analysis showed the combination of CD166/pS6 [hazard ratio, 9.42; 95% confidence interval, 2.36–37.59; p=0.002] to be the most significant predictor related with decreased cancer-specific survival. In addition, co-expression of CD44/CD166 (p=0.017), CD166/β-catenin (p=0.036), CD44/β-catenin (p=0.001), and CD44/CD166/β-catenin (p=0.001) were significant factors associated with liver metastasis. Conclusion: Specific combinations of CSC markers and β-catenin/mTOR signaling could be a significant predictor of poor survival in stage II CRC.
Abstract
Purpose: Wnt and mammalian target of rapamycin (mTOR) are major molecular signaling pathways associated with the development and progression of tumor, as well as the maintenance and proliferation of cancer stem cells (CSCs), in colorectal cancer (CRC). Identifying patients at risk of poor prognosis is important to determining whether to add adjuvant treatment in stage II CRC and thus improve survival. In the present study, we evaluated the prognostic value of Wnt, mTOR, and CSC markers as survival predictors in stage II CRC. Materials and Methods: We identified 148 cases of stage II CRC and acquired their tumor tissue. Tissue microarrays for immunohistochemical staining were constructed, and the expressions of CD166, CD44, EphB2, β-catenin, pS6 were evaluated using immunohistochemical staining. Results: The expressions of CD166 (p=0.045) and pS6 (p=0.045) and co-expression of pS6/CD166 (p=0.005), pS6/CD44 (p=0.042), and pS6/CD44/CD166 (p=0.013) were negatively correlated with cancer-specific survival. Cox proportional hazard analysis showed the combination of CD166/pS6 [hazard ratio, 9.42; 95% confidence interval, 2.36–37.59; p=0.002] to be the most significant predictor related with decreased cancer-specific survival. In addition, co-expression of CD44/CD166 (p=0.017), CD166/β-catenin (p=0.036), CD44/β-catenin (p=0.001), and CD44/CD166/β-catenin (p=0.001) were significant factors associated with liver metastasis. Conclusion: Specific combinations of CSC markers and β-catenin/mTOR signaling could be a significant predictor of poor survival in stage II CRC.
참고문헌 (39)
- Fedyanin M, "Role of stem cells in colorectal cancer progression and prognostic and predictive characteristics of stem cell markers in colorectal cancer", Curr Stem Cell Res Ther, 12, pp.19~30 (2017)
- Reya T, "Stem cells, cancer, and cancer stem cells", Nature, 414, pp.105~111 (2001)
- Lugli A, "Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer", Br J Cancer, 103, pp.382~390 (2010)
- Jing F, "Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases", Int J Oncol, 46, pp.1582~1588 (2015)
- Horst D, "Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166in colorectal cancer", Cancer Invest, 27, pp.844~850 (2009)
- Batlle E, "EphB receptor activity suppresses colorectal cancer progression", Nature, 435, pp.1126~1130 (2005)
- Pitule P, "Immunohistochemical detection of cancer stem cell related markers CD44 and CD133 in metastatic colorectal cancer patients", Biomed Res Int, 2014, pp.432139~ (2014)
- Shimokawa M, "Visualization and targeting of LGR5+ human colon cancer stem cells", Nature, 545, pp.187~192 (2017)
- de Sousa e Melo F, "A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer", Nature, 543, pp.676~680 (2017)
- Logan CY, "The Wnt signaling pathway in development and disease", Annu Rev Cell Dev Biol, 20, pp.781~810 (2004)
- Korinek V, "Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-", -colon carcinoma, 1997, pp.275, 1784~1787
- Morin PJ, "Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC", Science, 275, pp.1787~1790 (1997)
- Sung Noh Hong, "Genetic and epigenetic alterations of colorectal cancer", Intestinal research, 16(3), pp.327~337 (2018), 대한장연구학회
- Francipane MG, "mTOR pathway in colorectal cancer : an update", Oncotarget, 5, pp.49~66 (2014)
- Wullschleger S, "TOR signaling in growth and metabolism", Cell, 124, pp.471~484 (2006)
- Zhang YJ, "mTOR signaling pathway is a target for the treatment of colorectal cancer", Ann Surg Oncol, 16, pp.2617~2628 (2009)
- Prodromidis G, "Immunohistochemical analysis of the activation status of the Akt", mTOR, Int J Dent, pp.2013, 2013[DOI]
- Tanwar PS, "Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer", Carcinogenesis, 35, pp.546~553 (2014)
- Lugli A, "EphB2 expression across 138 human tumor types in a tissue microarray : high levels of expression in gastrointestinal cancers", Clin Cancer Res, 11, pp.6450~6458 (2005)
- Fleming M, "Colorectal carcinoma : pathologic aspects", J Gastrointest Oncol, 3, pp.153~173 (2012)
- Varghese A, "Chemotherapy for stage II colon cancer", Clin Colon Rectal Surg, 28, pp.256~261 (2015)
- Chang JY, "Comparison of clinical outcomes after endoscopic submucosal dissection and surgery in the treatment of early gastric cancer: a single-institute study", Medicine (Baltimore), 96, pp.e7210~ (2017)
- Benson AB 3rd, "American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer", J Clin Oncol, 22, pp.3408~3419 (2004)
- Labianca R, "Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 24(Suppl 6), pp.vi64~vi72 (2013)
- O’Connor ES, "Adjuvant chemotherapy for stage II colon cancer with poor prognostic features", J Clin Oncol, 29, pp.3381~3388 (2011)
- Ribic CM, "Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer", N Engl J Med, 349, pp.247~257 (2003)
- Sargent DJ, "Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer", J Clin Oncol, 28, pp.3219~3226 (2010)
- Medema JP, "Targeting the colorectal cancer stem cell", N Engl J Med, 377, pp.888~890 (2017)
- Merlos-Suárez A, "The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse", Cell Stem Cell, 8, pp.511~524 (2011)
- Fujishita T, "JNK signaling promotes intestinal tumorigenesis through activation of mTOR complex 1 in Apc(Δ716)mice", Gastroenterology, 140, pp.1556~1563 (2011)
- Bahrami A, "Therapeutic potential of targeting PI3K", AKT pathway in treatment of colorectal cancer : rational and progress, 2018, pp.119, 2460~2469
- Ribeiro KB, "KRAS mutation associated with CD44", CD166 immunoexpression as predictors of worse outcome in metastatic colon cancer, 2016, pp.16, 513~521
- Patel BB, "Age-related increase in colorectal cancer stem cells in macroscopically normal mucosa of patients with adenomas : a risk factor for colon cancer", Biochem Biophys Res Commun, 378, pp.344~347 (2009)
- Moon BS, "Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt", β-catenin signaling, 2014, pp.106, djt373~
- Bellizzi A, "Co-expression of CD133(+)", CD44(+)in human colon cancer and liver metastasis, 2013, pp.228, 408~415
- Suzuki H, "Nuclear beta-catenin expression at the invasive front and in the vessels predicts liver metastasis in colorectal carcinoma", Anticancer Res, 28, pp.1821~1830 (2008)
- Dalerba P, "Phenotypic characterization of human colorectal cancer stem cells", Proc Natl Acad Sci U S A, 104, pp.10158~10163 (2007)
- Su YJ, "Direct reprogramming of stem cell properties in colon cancer cells by CD44", EMBO J, 30, pp.3186~3199 (2011)
- Pandurangan AK, "Potential targets for prevention of colorectal cancer : a focus on PI3K", Akt, Asian Pac J Cancer Prev, pp.2013, 14[DOI]